Caitong International Asset Management Co. Ltd Has $359,000 Stock Position in Oscar Health, Inc. $OSCR

Key Points

• Caitong International Asset Management Co. Ltd increased its shares in Oscar Health by 385.9% in Q2, now holding 16,731 shares valued at $359,000.
• Insider Mario Schlosser sold 395,000 shares of Oscar Health, resulting in a 44.08% decrease in his ownership, now holding 501,148 shares.
• Oscar Health reported a revenue of $2.86 billion for the last quarter, with a negative EPS of ($0.89), surpassing analysts' expectations slightly.

Caitong International Asset Management Co. Ltd grew its holdings in shares of Oscar Health, Inc. (NYSE:OSCR - Free Report) by 385.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,731 shares of the company's stock after buying an additional 13,288 shares during the quarter. Caitong International Asset Management Co. Ltd's holdings in Oscar Health were worth $359,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Oscar Health by 3.7% during the first quarter. Vanguard Group Inc. now owns 19,698,442 shares of the company's stock valued at $258,247,000 after buying an additional 700,469 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Oscar Health by 4.1% during the first quarter. T. Rowe Price Investment Management Inc. now owns 11,826,245 shares of the company's stock valued at $155,043,000 after buying an additional 467,301 shares during the last quarter. Thrive Capital Management LLC grew its holdings in shares of Oscar Health by 33.4% during the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company's stock valued at $85,258,000 after buying an additional 1,588,395 shares during the last quarter. BIT Capital GmbH grew its holdings in shares of Oscar Health by 1.1% during the first quarter. BIT Capital GmbH now owns 4,521,445 shares of the company's stock valued at $59,276,000 after buying an additional 47,592 shares during the last quarter. Finally, Glynn Capital Management LLC grew its holdings in shares of Oscar Health by 14.0% during the first quarter. Glynn Capital Management LLC now owns 3,115,217 shares of the company's stock valued at $40,840,000 after buying an additional 381,980 shares during the last quarter. 75.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Mario Schlosser sold 395,000 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $18.43, for a total value of $7,279,850.00. Following the sale, the insider owned 501,148 shares of the company's stock, valued at $9,236,157.64. The trade was a 44.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 24.39% of the company's stock.

Oscar Health Stock Performance

Shares of OSCR stock opened at $19.63 on Friday. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of -24.23 and a beta of 1.89. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.86 and a current ratio of 0.86. Oscar Health, Inc. has a 52 week low of $11.20 and a 52 week high of $23.80. The firm's 50-day simple moving average is $18.80 and its two-hundred day simple moving average is $16.29.

Oscar Health (NYSE:OSCR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.01. The business had revenue of $2.86 billion for the quarter, compared to analyst estimates of $2.88 billion. Oscar Health had a negative net margin of 1.50% and a negative return on equity of 13.78%. The company's revenue for the quarter was up 29.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 earnings per share. As a group, equities analysts forecast that Oscar Health, Inc. will post 0.69 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on OSCR. Wells Fargo & Company boosted their price target on shares of Oscar Health from $10.00 to $14.00 and gave the stock an "underweight" rating in a report on Tuesday, October 7th. Zacks Research upgraded shares of Oscar Health from a "strong sell" rating to a "hold" rating in a report on Monday, October 13th. Barclays cut their price target on shares of Oscar Health from $17.00 to $11.00 and set an "underweight" rating on the stock in a report on Wednesday, July 23rd. Wall Street Zen cut shares of Oscar Health from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Finally, UBS Group restated a "sell" rating and set a $11.00 price target (down from $15.00) on shares of Oscar Health in a report on Tuesday, July 15th. Six investment analysts have rated the stock with a Hold rating and six have given a Sell rating to the company's stock. According to data from MarketBeat.com, Oscar Health presently has an average rating of "Reduce" and an average price target of $13.19.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.

Want to see what other hedge funds are holding OSCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oscar Health, Inc. (NYSE:OSCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.